Supernus to Host Third Quarter 2017 Earnings Conference Call
October 24 2017 - 4:15PM
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty
pharmaceutical company focused on developing and commercializing
products for the treatment of central nervous system (CNS)
diseases, today announced that the Company expects to report the
financial results for the third quarter of 2017 after 5:00 PM ET on
Monday, November 6, 2017.
Jack Khattar, President and Chief Executive Officer, and Greg
Patrick, Chief Financial Officer, will host a conference call to
present the third quarter 2017 business results on Tuesday,
November 7, 2017 at 9:00 AM ET. Following the management
presentation, the call will be open for questions.
A live webcast will be available at www.supernus.com.
Please refer to the information below for conference call
dial-in information. Callers should dial in approximately 10
minutes prior to the start of the call.
| Conference
dial-in: |
|
(877) 288-1043 |
| International
dial-in: |
|
(970) 315-0267 |
| Conference
ID: |
|
2899017 |
| Conference Call
Name: |
|
Supernus
Pharmaceuticals 3Q 2017 Earnings Conference Call |
Following the live call, a replay will be available on the
Company's website under the 'Investors' section. The webcast will
be available on the Company's website for 60 days following the
live call.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on developing and commercializing products for the
treatment of central nervous system diseases. The Company currently
markets Trokendi XR® (extended-release topiramate) for the
prophylaxis of migraine and the treatment of epilepsy, and Oxtellar
XR® (extended-release oxcarbazepine) for the treatment of epilepsy.
The Company is also developing several product candidates to
address large market opportunities in psychiatry, including SPN-810
for the treatment of Impulsive Aggression in ADHD patients and
SPN-812 for the treatment of ADHD.
CONTACTS:Jack A. Khattar, President and
CEOGregory S. Patrick, Vice President and CFOSupernus
Pharmaceuticals, Inc.Tel: (301) 838-2591
or
INVESTOR CONTACT:Peter VozzoWestwicke PartnersOffice: (443)
213-0505Mobile: (443) 377-4767Email: peter.vozzo@westwicke.com
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Apr 2023 to Apr 2024
